Ipamorelin vs MK-677: GHRP vs Ghrelin Agonist

Ipamorelin is a selective growth hormone-releasing peptide (GHRP-5) that acts as a GH-secretagogue receptor (GHS-R) agonist. It stimulates GH release from the anterior pituitary somatotrophs by activating GHS-R.

MK-677 (ibutamoren) is a non-peptide ghrelin receptor agonist that mimics the action of endogenous ghrelin. It activates the same GHS-R receptor as ipamorelin and other GHRPs, but is a small-molecule oral compound rather than a peptide.

Despite different chemical structures (peptide vs small molecule), both converge on GHS-R activation, making their mechanisms fundamentally similar — they just approach it differently.

Key difference: Ipamorelin is injectable (daily or multiple times daily); MK-677 is oral (once or twice daily).

Ipamorelin efficacy:

• GH stimulation: 2-4x elevation above baseline at typical doses
• Pulsatility: Stimulates GH pulses; relatively physiologic pattern
• Human studies: 10-15 published studies; Phase 2 development
• Dosing: 0.1-0.3 mg subcutaneously daily or 2-3x daily
• Onset: 15-30 minutes; peaks at 30-60 minutes
• Duration: 2-4 hours of elevated GH per dose
• Evidence quality: Moderate; some human data but no Phase 3

MK-677 efficacy:

• GH stimulation: 2-5x elevation above baseline depending on dose
• Pulsatility: Stimulates GH pulses; maintains some physiologic pattern
• Human studies: 15-20 published studies; more extensive than ipamorelin
• Dosing: 10-25 mg orally daily (convenient)
• Onset: Slower than ipamorelin (60-120 minutes)
• Duration: 4-6+ hours of elevated GH; more sustained elevation
• Evidence quality: Moderate-to-good; more human studies than ipamorelin

Comparative data:

Both produce similar GH elevation (~2-4x baseline). MK-677 may sustain GH elevation longer due to oral absorption kinetics. Ipamorelin may produce more physiologic pulsatility due to shorter onset/offset.

Ipamorelin side effects:

• Injection site: Mild discomfort, erythema (injectable)
• Systemic: Generally well-tolerated; minimal side effects
• Cortisol/prolactin: Minimal suppression (unlike some GHRPs)
• Food intake: Modest increase in appetite (ghrelin-like)
• Sleep: Generally improves GH-dependent sleep quality
• Carpal tunnel: Rare; GH-related

MK-677 side effects:

• Appetite: Increased appetite (ghrelin mimic); more pronounced than ipamorelin
• Water retention: 10-20% of users report mild edema, especially at higher doses
• Insulin sensitivity: May slightly reduce sensitivity (carbohydrate metabolism effect)
• Prolactin: Modest increase (~20% elevation)
• Cortisol: Minimal effect
• Joint pain: Some reports, likely GH-related
• Sleep: Generally improves

Practical tolerability:

Ipamorelin is typically better tolerated (fewer systemic side effects), while MK-677 is more convenient (oral) but may cause appetite increase and water retention.

Choose Ipamorelin if:

• You prefer injectable GH secretagogue for physiologic GH pulsatility
• You want minimal systemic side effects (well-tolerated)
• You accept multiple daily injections (typically once or twice daily)
• You prioritize pure GHS-R agonism without ghrelin's appetite drive
• Cost is not a barrier ($250-400/month compounded)

Choose MK-677 if:

• You prefer oral once-daily dosing (convenient)
• You want more sustained GH elevation over pulsatile pattern
• You accept increased appetite and potential water retention
• You have robust oral absorption (GI must be functional)
• You want slightly more published human evidence
• Cost is lower ($150-250/month)

Direct comparison:

Bottom line:

Both are reasonable GH secretagogues. If you value convenience and sustained GH elevation, choose MK-677. If you prioritize physiologic pulsatility and minimal side effects, choose ipamorelin. Neither is proven for anti-aging; both are investigational for that use.